Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study.
J Eur Acad Dermatol Venereol
; 36(8): 1284-1291, 2022 Aug.
Article
em En
| MEDLINE
| ID: mdl-35366361
ABSTRACT
INTRODUCTION:
Treatment with biologics often leads to clearance of psoriasis. However, some patients do repeatedly fail to respond and/or lose an achieved response (treatment refractory) to the biologic, whereas other patients achieve excellent response to one biologic and remain clear of psoriasis for several years (super-responders).OBJECTIVE:
To identify and characterize patients with treatment refractory psoriasis and patients who are super-responders to biologic treatment. MATERIAL ANDMETHODS:
Patients registered in DERMBIO between January 2007 and November 2019 were included. Patients were categorized as being treatment refractory if they had had treatment failure to ≥3 biologics targeting ≥2 different pathways. Super-responders were patients treated with their first biologic for minimum 5 years without an absolute psoriasis area and severity index (PASI) > 3 between 6 months and 5 years of treatment. All remaining patients from DERMBIO served as comparators.RESULTS:
In total, 3280 patients were included with a mean age of 45.0 years. 1221 (37%) of the patients were females. Of the included patients, 214 (6.5%) were categorized as treatment refractory and 207 (6.3%) were categorized as super-responders. Treatment refractory patients had higher mean body weight (100.6 kg vs. 90.6 kg, P < 0.0001) and higher mean BMI (32.2 vs. 29.4, P < 0.0001) compared with the rest of patients in DERMBIO. Super-responders had higher socioeconomic status and fewer comorbidities compared with the comparator group (P < 0.0001).CONCLUSION:
A small proportion of patients with psoriasis treated with biologics are either super-responders or treatment refractory. Treatment refractory patients have higher body weight, whereas super-responders have fewer comorbidities and higher socioeconomic status.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Psoríase
/
Produtos Biológicos
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article